Pinterest • The world’s catalog of ideas

Marriott International Stock #tradestocks, tradingcfds, stockprices, marstock, stockcharts

from Reuters India

AstraZeneca gets up to $500 million from Lilly for Alzheimer's drug

AstraZeneca to partner with Eli Lilly on Alzheimer's drug | Reuters

Eli Lilly’s revenue has actually declined over the past five years, in large part due to expiring patents. Operating profit has shrunk from $6.5 billion all the way down to $2.3 billion. Meanwhile, Eli Lilly’s profit margin has been cut nearly in half. It’ll be very challenging to return margins to their prior levels for a variety of reasons. For example, the patent on Cialis, a high-margin erectile dysfunction drug, expires in 2017.

Company Update: Eli Lilly & Company (NYSE:LLY) – Lilly and Sanford-Burnham Announce Collaboration to Investigate Immunological Therapies By Heather Cunnings, on May 14th, 2015


“Eli Lilly and the pharmaceutical industry were the only winners benefiting from $101.2 million of public funds and the public is not allowe...


Point Roberts WA, New York, NY - February 19, 2014 ( Biotech Newswire) global news source covering leading sectors including biotech and pharma reports on companies in the sector targeting pancreatic cancer. Stocks mentioned include NewLink Genetics (NLNK), Sunshine Biopharma Inc. ( OTCBB: SBFM ), Eli Lilly and Company (NYSE:LLY) and Celgene (NASDAQ:CELG).